Background: The aim of this study was to evaluate the safety and efficacy of indirect thrombolysis via the superior mesenteric artery (SMA) in patients with acute portal vein thrombosis.
Methods: Over 10 years, we studied the safety and efficacy of indirect thrombolysis via the SMA in 34 patients with acute portal vein thrombosis. Eighteen patients were categorized as the systemic thrombolysis (ST) group and 16 as the catheter thrombolysis (CT) group. The ST group was administered low-molecular-weight heparin, and patients in the CT group received catheter thrombolysis. Clinical data, such as comorbidities, laboratory test results, therapeutic methods, and prognosis, were recorded. All the patients underwent a routine clinical follow-up that was performed by inpatient examinations or outpatient visits at a mean follow-up time of 34 months.
Results: The thrombus score was significantly higher in the ST group (3.67 ± 1.19) than in the CT group (2.38 ± 0.62) after 2 weeks of treatment (P < 0.05). The average period of symptom alleviated was longer in the ST group (3.29 ± 1.59 days) than in the CT group (2.07 ± 0.73 days, P < 0.05). Five patients (4 in the ST group and 1 in the CT group) underwent a laparotomy because of peritonitis after thrombolysis for 24 hr. One patient died of a malignant tumor after 18 months.
Conclusions: Indirect thrombolysis via the SMA is safer and more effective for patients with portal vein thrombosis compared with systemic thrombolysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.avsg.2016.06.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endovascular interventions in cancer patients with compromise of the mediastinal vasculature: a review.
Mediastinum
May 2024
Department of Interventional Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The mediastinal vasculature can be affected by various etiologies in cancer patients. Both direct and indirect sequela of cancer may result in life-threatening clinical presentations. Tumor growth may cause vessel narrowing and decreased blood flow from either extrinsic mass effect, invasion into the vascular wall, or tumor thrombus within the lumen.
View Article and Find Full Text PDFPotential Predictive Value of Platelet Distribution Width for Functional Outcome After Ischemic Stroke.
Mol Neurobiol
October 2024
Institute of Cerebrovascular Diseases Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Beijing, 100053, China.
Article Synopsis
- Complete blood cell count (CBC) testing, commonly used in clinical settings, has been linked to ischemic stroke outcomes, but the exact cause-and-effect relationships remain unclear.
- This study investigates the causal links between CBC indices, specifically focusing on platelet distribution width (PDW), and patient outcomes three months after ischemic stroke, using data from large genetic databases.
- The findings suggest that higher genetically determined PDW is associated with worse outcomes post-stroke, although it does not significantly improve predictive models for stroke outcomes and its connection to stroke prognosis may be indirect, potentially influenced by factors like serum glucose levels.
Venous thrombolysis prior to mechanical thrombectomy reduces glycocalyx damage in patients with acute ischemic stroke.
Front Neurol
August 2024
Neurosurgery Department, Liaocheng People's Hospital, Liaocheng, China.
Introduction: The administration of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) in the treatment of acute ischemic stroke (AIS) has been a subject of debate, and its potential benefits remain uncertain. This retrospective study aimed to investigate the effect of preoperative IVT on glycocalyx damage in patients with cerebral ischemia-reperfusion injury (IRI).
Methods: A cohort of 106 patients with acute large vessel occlusion in the anterior circulation treated with mechanical thrombectomy was enrolled.
Anticoagulation in Pediatric Patients.
Tech Vasc Interv Radiol
June 2024
Department of Pediatrics, Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO; Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.
The use of antithrombotic agents is increasing in infants, children and adolescents. The more recent routine inclusion of children in FDA-monitored clinical trials has propelled the rapid accumulation of safety and efficacy data on these agents in pediatric patients. Antithrombotic agents in current use include indirect or antithrombin-dependent anticoagulants, intravenous direct thrombin inhibitors, direct oral anticoagulants (DOACs) targeting thrombin or factor Xa, antiplatelet agents and thrombolytic therapies.
View Article and Find Full Text PDFAnti-inflammatory Effect of Batroxobin Combined With Anticoagulation in Patients With Cerebral Venous Thrombosis.
Clin Appl Thromb Hemost
September 2024
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- Inflammation plays a crucial role in the development of cerebral venous thrombosis (CVT), prompting a study on the anti-inflammatory effects of batroxobin alongside anticoagulation treatment.
- The study involved two groups: one receiving batroxobin combined with anticoagulation and the other receiving only anticoagulation, analyzing their effects on various inflammatory indicators.
- Results showed that batroxobin significantly reduced inflammatory markers like fibrinogen and the platelet-lymphocyte ratio, and its effectiveness improved with more frequent administration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!